SCHEDULE 13G/A: Lundbeckfond Invest A/S and CEO Lene Skole Disclose 1.6% Stake in OnKure Therapeutics

Lundbeckfond Invest A/S and its Chief Executive Officer, Lene Skole, have jointly filed an amended Schedule 13G, reporting beneficial ownership of 1.6% of OnKure Therapeutics, Inc.'s Class A Common Stock as of December 31, 2024.

Summary

• Lundbeckfond Invest A/S and Lene Skole (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in OnKure Therapeutics, Inc.
• As of December 31, 2024, the Reporting Persons beneficially own an aggregate of 203,122 shares of OnKure Therapeutics, Inc.'s Class A Common Stock.
• This ownership represents 1.6% of the Issuer's Class A Common Stock outstanding.
• The percentage is calculated based on 12,652,890 shares of Class A Common Stock outstanding as of November 4, 2024, as reported in OnKure Therapeutics' Quarterly Report on Form 10-Q filed on November 7, 2024.
• Lundbeckfond Invest A/S, a private Danish corporation, holds the 203,122 shares.
• Lene Skole, a citizen of Denmark and the Chief Executive Officer of Lundbeckfond Invest A/S, is deemed to have sole voting and dispositive power over these shares, as delegated by Lundbeckfond's directors.

Sentiment

Score: 5

Explanation: The document is a neutral, factual disclosure of beneficial ownership, as required by SEC regulations. It does not contain information that would inherently suggest a positive or negative sentiment regarding the company's performance or prospects.

Positives

• The filing provides transparency regarding the beneficial ownership of a significant institutional investor, Lundbeckfond Invest A/S, and its executive, Lene Skole.
• The continued holding of shares by Lundbeckfond Invest A/S may signal ongoing confidence in OnKure Therapeutics, Inc. by this investor.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding the Issuer's future outlook.

Management Comments

• Lene Skole is the Chief Executive Officer of Lundbeckfond Invest A/S and may be deemed to have sole power to vote and dispose of the shares held by Lundbeckfond.
• The directors of Lundbeckfond have delegated voting and dispositive power with respect to the shares held by Lundbeckfond to Skole.

Industry Context

This filing is a routine regulatory disclosure of a significant ownership stake by an institutional investor in a publicly traded company. It does not provide specific insights into broader industry trends or competitive dynamics, but rather reflects an investment decision within the biotechnology or pharmaceutical sector where OnKure Therapeutics operates.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant ownership stakes, allowing other investors to see who holds substantial portions of the company's stock.

Key Dates

Keywords

OnKure Therapeutics, Lundbeckfond Invest A/S, Lene Skole, Schedule 13G, beneficial ownership, Class A Common Stock, SEC filing, institutional investment, equity stake